-
GLUT Related Products (58)
Related Products (58)
-
PeS-9
0 ImagesCat. No.: HY-174377PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors.
-
PTP1B-IN-34
0 ImagesCat. No.: HY-181700PTP1B-IN-34 is an orally active, selective, non-competitive PTP1B inhibitor, with an IC50 value of 0.64 μM and a Ki value of 1.15 μM against human PTP1B. PTP1B-IN-34 reduces blood glucose levels in diabetic mice. PTP1B-IN-34 can be used in research related to type 2 diabetes.
-
VB1-050
0 ImagesCat. No.: HY-P990674
-
GTP-γ-S
0 ImagesCat. No.: HY-137677CAS No.: 37589-80-3Synonyms: Guanosine 5'-[γ-thio]triphosphateGTPγS (Guanosine 5'-[γ-thio]triphosphate) is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS to couple with G- protein α, to study its effect on kinase activity. GTPγS acts as a component of lysis buffer.
-
Rapaglutin E
0 ImagesCat. No.: HY-176051Synonyms: RgERapaglutin E (RgE) is a glucose transporter (GLUT) inhibitor. Rapaglutin E exhibits dose-dependent inhibition of [3H]-2DG uptake in A549, Jurkat T, PANC10.05, and RBC, with IC50 values 8.9 nM, 3.1 nM, 35.5 nM, 74.2 nM. Rapaglutin E inhibits cell proliferation in A549, PANC10.05, HeLa, Jurkat T, and HEK293T cells.
-
Physagulide Y
0 ImagesCat. No.: HY-163139Physagulide Y (2), a withanolide with anticancer activity, is a GLUT1 inhibitor.
-
Brevifolincarboxylic acid (Standard)
0 ImagesCat. No.: HY-N4095RCAS No.: 18490-95-4Brevifolincarboxylic acid (Standard) is the analytical standard of Brevifolincarboxylic acid (HY-N4095). This product is intended for research and analytical applications. Brevifolincarboxylic acid is a phenolic compound. Brevifolincarboxylic acid can be isolated from Duchesnea chrysantha. Brevifolincarboxylic acid inhibits α-glucosidase with an IC50 value of 323.46 μM. Brevifolincarboxylic acid has an inhibitory effect on the aryl hydrocarbon receptor (AhR). Brevifolincarbacid scavenges ROS. Brevifolincarbacid restores the glucose uptake activity of myotubes. Brevifolincarboxylic acid has antitumor activity against lung and gastric cancer. Brevifolincarbacid can be used in the study of diabetes and inflammatory diseases.
-
BAY-876 (Standard)
0 ImagesCat. No.: HY-100017RCAS No.: 1799753-84-6BAY-876 (Standard) is the analytical standard of BAY-876 (HY-100017). This product is intended for research and analytical applications. BAY-876, a chemical probe, is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis.
-
SBI-477 analog
0 ImagesCat. No.: HY-124417CAS No.: 2073059-56-8SBI-477 (compound 41) analog inhibits intracellular lipid accumulation, increase celluar glucose uptake.
-
Rubusoside (Standard)
0 ImagesRubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
-
SLC2A1 modulator-1
0 ImagesCat. No.: HY-180874CAS No.: 393845-92-6SLC2A1 modulator-1 is a SLC2A1 modulator.
-
BAY-588
0 ImagesCat. No.: HY-121086CAS No.: 1799759-24-2BAY-588 is a selective inhibitor of GLUT1 with an IC50 value of 1.18μM.
-
4,6-O-Ethylidene-α-D-glucose (Standard)
0 ImagesCat. No.: HY-N7433RCAS No.: 13224-99-2Synonyms: Ethylidene-glucose (Standard)4,6-O-ethylidene-α-D-glucose (Ethylidene-glucose), a glucose derivative, is a competitive exofacial binding-site inhibitor on glucose transporter 1 (GLUT1) with a Ki of 12 mM for wild-type 2-deoxy-D-glucose transport.
-
Sennidin A (Standard)
0 ImagesSennidin A (Standard) is the analytical standard of Sennidin A. This product is intended for research and analytical applications. Sennidin A, isolated from the leaves of Cassia angustifolia, inhibits HCV NS3 helicase, with an IC50 of 0.8 μM. Sennidin A induces phosphorylation of Akt and glucose transporter 4 (GLUT4) translocation. Sennidin A stimulates the glucose incorporation.
-
Fasentin (Standard)
0 ImagesCat. No.: HY-101849RCAS No.: 392721-37-8Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.
-
α-lipoic acid derivative 1
0 ImagesCat. No.: HY-120974CAS No.: 691410-93-2α-Lipoic Acid Derivative 1 (Compound AN-7) is an α-lipoic acid derivative that enhances glucose transport in skeletal muscle by releasing active α-lipoic acid (LA), significantly improving glucose metabolism. In L6 skeletal muscle cells, α-Lipoic Acid Derivative 1 significantly increases glucose transport rates, approximately 12 times more potent than the parent compound α-lipoic acid (HY-N0492). In a mild diabetic mouse model, 10 mg/kg of α-Lipoic Acid Derivative 1 administered for two weeks significantly reduced blood glucose levels by 39%. α-Lipoic Acid Derivative 1 shows significant potential in research related to glucose metabolism in diabetes.
